A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into the Cerebrospinal Fluid of Participants With Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
- Conditions
- Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disease DementiaMedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2022-501644-15-00
- Lead Sponsor
- Biogen Idec Research Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 735
Must meet all the clinical criteria for MCI due to AD (Stage 3) or mild AD dementia (Stage 4) according to the National Institute on Aging at National Institutes of Health and the Alzheimer's Association (NIA-AA) and must have the following at Screening Visit 1: 1) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Delayed Memory Index score of =85, indicative of objective evidence of memory impairment 2) CDR global score of 0.5 for MCI due to AD or 0.5 or 1 for mild AD dementia 3) MMSE score of 22 to 30 (inclusive) 4) CDR Memory Box score of =0.5, Evidence of amyloid pathology as measured by positive emission tomography (PET) or cerebrospinal fluid (CSF) sampling, Note: Other protocol defined Inclusion/Exclusion criteria may apply
Known allergy to BIIB080 or a history of hypersensitivity to any of the inactive ingredients in the drug product, Contraindications to having a brain magnetic resonance imaging (MRI) [e.g., MRI-incompatible pacemaker; MRI-incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed]. If the MRI compatibility of implanted devices is unknown, the participant must be excluded from the study, Current enrolment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 52 weeks prior to the Baseline Visit, Note: Other protocol defined Inclusion/Exclusion criteria may apply, Previous participation in this study or previous studies with BIIB080, Use of non-disease–modifying AD medications (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine) at doses that have not been stable for at least 8 weeks prior to Screening Visit 1 and during the screening period up to Study Day 1, Prior participation in any active or passive immunotherapy study targeting Aß, unless documentation of receipt of placebo is available, Prior participation in any passive immunotherapy study targeting tau, unless the last administration occurred 6 months or 5 half-lives, whichever is sooner, prior to Screening or documentation of receipt of placebo is available, Participation in any study involving an investigational treatment targeting tau that is not an immunotherapy, unless documentation of receipt of placebo is available, Participation in a study of any other agent(s) [including gene therapy] not included in exclusion criteria 4, 5, and 6 with a purported disease-modifying effect in AD, unless documentation of receipt of placebo is available, Current use or previous use of medications with a purported disease-modifying effect in AD, outside of investigational studies, Any vaccination given within 10 days prior to Day -1. Coronavirus disease 2019 (COVID-19) vaccinations using RNA or deoxyribonucleic acid (DNA) technology are allowed during the study, as well as other types of immunization /vaccination/ booster, except during the 10 days before and after clinic visits
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method